Literature DB >> 15032699

SNC 80 and related delta opioid agonists.

S N Calderon1, A Coop.   

Abstract

The discovery of the selective delta (delta) opioid agonists SNC 80 and BW373U86, which possess a diarylmethylpiperazine structure unique among opioids, was a major advance in the field of delta-opioid ligands. Much research has been performed to uncover the structure-activity relationships (SAR) of this class of ligands and also to compare the diarylmethylpiperazines with the traditional morphinan-based delta opioids. This review focuses on the development of the SAR of this unique series of ligands, and discusses questions which remain unanswered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15032699     DOI: 10.2174/1381612043453054

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

Review 1.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 2.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

3.  The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors.

Authors:  Matthew D Metcalf; Ajay S Yekkirala; Michael D Powers; Kelley F Kitto; Carolyn A Fairbanks; George L Wilcox; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2012-05-22       Impact factor: 4.418

4.  Delta opioid receptor ligands modulate anxiety-like behaviors in the rat.

Authors:  Shane A Perrine; Brian A Hoshaw; Ellen M Unterwald
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

5.  Inflammatory pain is enhanced in delta opioid receptor-knockout mice.

Authors:  Claire Gavériaux-Ruff; Laurie A Karchewski; Xavier Hever; Audrey Matifas; Brigitte L Kieffer
Journal:  Eur J Neurosci       Date:  2008-05-29       Impact factor: 3.386

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.